NagaChalasaniMD

PubMed

• 4410 citations
  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
  Naga Chalasani, Zobair M. Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi
  Hepatology. 2018-01-01
• 1587 citations
  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
  Brent A. Neuschwander-Tetri, Rohit Loomba, Arun J. Sanyal, Joel E. Lavine, Mark L. Van Natta
  Lancet. 2015-03-14
• 28 citations
  Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies.
  Scott Vanderbeck, Joseph Bockhorst, David E. Kleiner, Richard A. Komorowski, Naga Chalasani
  Human Pathology. 2015-05-01

Journal Articles

• In a Pilot Study, Reduced Fatty Acid Desaturase 1 Function Was Associated with Nonalcoholic Fatty Liver Disease and Response to Treatment in Children  
  Jingmei Lin, Naga P Chalasani, Nature
• Liver Stiffness Measurements in Patients with Non‐Cirrhotic Portal Hypertension – the Devil Is in the Details  
  Niharika Samala, Raj Vuppalanchi, Naga Chalasani, Hepatology
• Common Variation near IRF6 Is Associated with IFN-Β-induced Liver Injury in Multiple Sclerosis  
  Joshua C Denny, Zongqi Xia, Naga Chalasani, Nature
• Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the drug induced liver injury network  
  Hayashi PH, Barnhart HX, Fontana RJ, Chalasani N, Davern TJ, Talwalkar JA, Reddy KR, Stolz AA, Hoofnagle JC, Rockey DC, Liver Int, 1/24/2014
• Relationship between changes in serum keratin 18 fragments and changes in liver histology in adults and in children with nonalcoholic fatty liver disease  
  Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Yates K, Masuoka HC, Neuschander-Tetri B, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer J, Lavine JE, ..., Clin Gastroenterol Hepatol, 1/17/2014
• Drug induced liver injury due to statins: experience of the US Drug Induced Liver Injury Network  
  Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL, Hepatology, 1/2/2014
• Drug Induced Liver Injury  
  Chalasani N & Hayashi PH (Co-editors), Seminars Liver Disease, 1/1/2014
• Drug-induced hepatic steatosis  
  Amacher DE, Chalasani N, Semin Liver Dis, 1/1/2014
• An assessment of statin liver safety - 2014 update  
  Bays H, Cohen DE, Chalasani NP, Harrison SA, J Clin Lipidol, 1/1/2014
• The diagnosis and Management of idiosyncratic drug induced liver injury: Practice guideline by the American College of Gastroenterology  
  Chalasani N, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ on behalf of the American College of Gastroenterology, Am J Gastroenterology, 1/1/2014
• Trials and tribulations in drug development for nonalcoholic steatohepatitis (Editoria)  
  Sanyal AJ, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• HIV-coinfection profoundly alters intrahepatic chemokine but not inflammatory cytokine profiles in HCV-infected subjects  
  Hu S, Ghabril M, Amet T, Hu N, Dyrd D, Vuppalanchi R, Saxena R, Desaif M, Johnson R, Gupta S, Chalasani N, Yu Q, PLoS, 1/1/2014
• Serum hepcidin levels are associated with obesity but not liver disease  
  Vuppalanchi R, Troutt JS, Konrad RJ, Ghabril M, Saxena R, Bell LN, Kowdley KV, Chalasani N, Obesity, 1/1/2014
• Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations  
  Kleiner DE, Chalasani N, Lee W, Fontana R, Bonkovsky HL, Watkins PB, Hayashi P, Davern T, Navarro V, Reddy KR, et al, Hepatology, 1/1/2014
• Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease  
  Corey KE, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• There is substantial morbidity and mortality associated with idiosyncratic drug induced liver injury: results from the DILIN prospective study  
  Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwalkar JA, Gastroenterology, 1/1/2014
• IL-12/Th1 and IL-23/Th17 biliiary microenvironment in primary biliary cirrhosis: Implications for therapy  
  Yang CY, Ma X, Tsuneyama K, Takahashi T, Chalasani N, Yang GX, Leung PSC, Ansari AA, Wu L, Strauss R, Gershwin ME, Hepatology, 1/1/2014
• Genetic polymorphism of cytochrome P450 4F2, vitamin E and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVEN...  
  Athinarayan S, Wei R, Bai S, Traber MG, Yates K, Cummings OW, Molleston JP, Liu W, Chalasani N, PLoS ONE, 1/1/2014
• Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices  
  Kahloon A, Chalasani N, Dewitt J, Liangpunsakul S, Vinayek R, Ghabril M, Chiorean M, Digestive Diseases and Sciences, 1/1/2014
• Nodular regenerative hyperplasia due to trastuzumab emtansine  
  Force J, Saxena R, Schneider B, Storniolo AM, Sledge GW, Chalasani N, Vuppalanchi R, J Clinical Oncology, 1/1/2014
• An integrated omics analysis of human liver tissue revealed a mechanistic pathway underlying the role of FADS1 in hepatic lipid accumulation  
  Wang L, Athinarayanan S, Chalasani N, Zhang M, Liu W, Hepatology, 1/1/2014
• Genetic control of hepatic PNPLA3 transcription and a high-risk haplotype identifies a modifier allele for 148M and a high risk haplotype supporting the gain-of-functi...  
  Liu W, Anstee QM, Wang X, Gamazon ER, Athinarayanan S, Liu YL, Darlay R, Cordell HJ, the FLIP investigators, Daly AK, Day CP, Chalasani N, Gastroenterology, 1/1/2014
• Serum metabolic signatures of primary biliary cirrhosis and primary sclerosing cholangitis  
  Bell LN, Comerford M, Vuppalanchi R, Chalasani N, Liver International, 1/1/2014
• Clinical and histopathologic features of azithromycin-induced liver injury  
  Martinez M, Vuppalanchi R, Fontana R, Stolz A, Kleiner DE, Watkins PB, Barnhart H, Hoofnagle J, Chalasani N, Clinical Gastroenterology and Hepatology, 1/1/2014
• Obeticholic acid for nonalcoholic steatohepatitis: a randomized, placebo-controlled trial  
  Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek M, Chalasani N, Dasarathy S, e t al, New Engl J Med, 1/1/2014
• Join now to see all

Books/Book Chapters

• Drug Induced Liver Disease. 
  Vuppalanchi R, Chalasani NEditors: Kaplowitz N, DeLeve L.Marcel Dekker PublicationsEdition 3rd,2012
• Drug Induced Liver Injury: Epidemiology in the Western Countries. 
  Bell LN, Chalasani N2009
• Hepatology: A Textbook of Liver Disease. 
  Chapter: The Liver in Systemic Disease. 
  Chalasani N, Cummings OWEditors: Zakim D, Boyer TD.WB Saunders, Philadelphia, PAEdition 4th,2002
• Drug Induced Liver Disease. 
  Chapter: Hepatotoxicity due to cardiovascular and endocrinological drugs. 
  Bhardwaj S, Chalasani NEditors: Kaplowitz N, DeLeve L.Marcel Dekker Publications
• Evidence based Gastroenterology and Hepatology. 
  Chapter: Drug Induced Liver Injury. 
  Polson J, Chalasani NEditors: Younossi Z.Oxford PublicationsEdition 1st,
• Practical Gastroenterology and Hepatology. 
  Chapter: Drug Induced Liver Injury. 
  Bjornsson E, Chalasani NEditors: Talley N (Leader Editor), Lindor K and Vargas H.
• In Cecil's Text Book of Medicine. 
  Chapter: Alcoholic liver disease & Nonalcoholic fatty liver disease. 
  Chalasani NEditors: Ausiello & Goldman.Edition 23rd,
• Join now to see all

Abstracts/Posters

• Automatic quantification of liver histology in NAFLD. A promising tool to facilitate better histological characterization.
  Vanderbeck S, Bockhorst J, Komorowski R, Kleiner DE, Chalasani NP, Gawrieh S, Gastroenterology, DDW, 1/1/2014
• Little evidence for serious outcome in patients with chronic liver disease receiving potentially hepatotoxic drugs.
  Bjornsson E, Einarsdottir R, Jacobsen E, Chalasani NP, Gastroenterology, DDW, 1/1/2014
• Idiosyncratic drug induced liver injury in the United States: a report of 1257 prospectively enrolled patients.
  Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, et al, American College of Gastroenterology 2014 Annual Meeting, 1/1/2014
• Drug induced liver injury (DILI) in patients with underlying liver disease has worse prognosis: results from the drug induced liver injury network (DILIN) prospective ...
  Chalasani N, Bonkovsky HL, Fontana RJ, Gu J, Hayashi P, et al, AASLD Annual Meeting, 1/1/2014
• A comprehensive assessment of environmental exposures among 1000 North American primary sclerosing cholangitis patients with and without inflammatory bowel disease.
  Eaton JE, Juran BD, Atkinson EJ, Schlicht EM, Xie X, Andrade M, Luketic VA, Odin J, Koteish AA, Kowdley KV, Chopra KB, Hirshfield GM, Chalasani NP, Lazaridis LN, AASLD, 1/1/2014
• Disturbed sleep in highly prevalent in patients with cirrhosis and is independently associated with poor quality of life.
  Jackson M, Orman ES, Vuppalanchi R, Chalasani N, Ghabril M, AASLD Annual Meeting, 1/1/2014
• Global serum metabolomic profiling identifies a distinct metabolomic signature in patients with cirrhosis who have altered sleep pattern.
  Ghabril M, Jackson M, Bell LN, Gunst PR, Ornam ES, Vuppalanchi R, Chalasani N, AASLD Annual Meeting, 1/1/2014
• Delirium is related to hepatic encephalopathy and is associated with poor outcomes in cirrhosis.
  Orman ES, Perkins A, Ghabril M, Khan BA, Chalasani N, Boustani MA, AASLD annual meeting, 1/1/2014
• Clinical characteristics and outcomes of acute alcoholic hepatitis - preliminary report from the Translation al Research and Evolving Alcoholic Hepatitis Treatment (TR...
  Liangpunsakul S, Shah V, Sanyal A, Katz B, Kamath P, Saberi B, Ren Z, Puri P, Chalasani N, Crabb DW, Radaeva S, AASLD annual meeting, 1/1/2014
• Do liver transplant centers need different bench marks for quality metrics for managing hospitalized patients with cirrhosis.
  Ghabril M, Kwo PY, Tector J, Agrawal S, Chalasani N, AASLD annual meeting, 1/1/2014
• Fibroblast growth factor 21 treatment improves atherogenic diet-induced liver injury and metabolic syndrome in Ossabaw miniature swine.
  Gawrieh S, Alloosh M, Sheridan R, Liang T, Masuoka MC, Chalasani N, Sturek M, AASLD annual meeting, 1/1/2014
• Autoimmune hepatitis with inflammatory bowel disease in distinct and may be more refractory to traditional treatment.
  Bailey B, Fischer M, Vuppalanchi R, Ghabril M, Gawrieh M, Orman ES, Chalasani N, Lammert C, ACG annual meeting, 1/1/2014
• Biochemical response is associated with improved survival in patients with autoimmune hepatitis and advanced disease.
  Baily B, Orman ES, Vuppalanchi R, Ghabril M, Gawrieh S, Chalasani N, Lammert C, AASLD annual meeting, 1/1/2014
• Urea cycle disorders in patients with cirrhosis and hepatic encephalopathy.
  Ghabril M, Gotur R, Weber R, Hainline B, Chalasani N, AASLD annual meeting, 1/1/2014
• Early phase 1 results of GR-MD-02, a galectin-3 inhibitor, in patients with NASH and advanced fibrosis.
  Harrison SA, Chalasani N, Lawitz E, Noureddin M, Sanyal A, Schiano T, Siddique M, Tetri B, Traber PG, AASLD annual meeting, 1/1/2014
• NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.
  Corey KE, Vuppalanchi R, Wilson L, Cummings OW, Chalasani N, for the NASH CRN, AASLD Annual Meeting, 1/1/2014
• Profiles of serum microRNAs in acute drug-induced liver injury and their prognostic significance.
  Russo MW, Norton JB, Anderson W, Steurwald M, Barnhart H, Chalasani N, Fontana R, Hayashi P, Serrano J, Bonkosky HL, AASLD Annual Meeting, 1/1/2014
• Examination of dietary factors in autoimmune hepatitis utilizing social media and crowdsourcing.
  Comerford M, Chalasani N, Lammert C, AASLD Annual Meeting, 1/1/2014
• Portal vein thrombosis is a risk factor for early mortality and graft loss post liver transplantation: analysis of the UNOS database.
  Ghabril M, Kwo PY, Tector J, Lacerda M, Chalasani N, Agrawal S, AASLD Annual Meeting, 1/1/2014
• Cholestatic drug reactions are more likely to cause persistent liver injury and impaired quality of life during prolonged follow-up: results from the DILIN Prospective...
  Fontana RJ, Hayashi P, Reddy KR, Kleiner DE, Philips T, Barnhart H, Talwalkar J, Chalasani N, Lee W, Stolz A, Davern T, Watkins PB, Serrano J, Hoofnagle JH, AASLD Annual Meeting, 1/1/2014
• Genetic polymorphism of cytochrome P450 4F2 (CYP4F2) and histological response to vitamin E treatment in children and adults with nonalcoholic fatty liver disease.
  Dutta A, Chalasani N, DDW, 1/1/2013
• Changes in serum cytokeratin 18 levels significantly predict changes in liver histology in adults with nonalcoholic steatohepatitis.
  Vuppalanchi R, Deppe R, Yates K, Comerford M, Masuoka H, Tetri B, Loomba R, Brunt E, Kleiner D, Tonascia J, Chalasani N for the NASH CRN, DDW, 1/1/2013
• Novel genetic loci associated with steatohepatitis and fibrosis in Hispanic boys with nonalcoholic fatty liver disease.
  Lavine JE, Chalasani NP, Guo X, Kwon S, Schwimmer J, Molleston JP, Loomba R, Brunt EM, Chen IYD, Goodarzi M, Taylor KD, Yates KP, Unalp-Arida A, Rotter JI, DDW, 1/1/2013
• Mapping expression quantitative traits loci (eQTL) for PNPLA3gene identifies additional SNPs associated nonalcoholic fatty liver disease independent of rs738409.
  Wang X, Onjiko R, Anstee QM, Ratziu V, Liu YL, Cordell HJ, Darlay R, Day CP, Daly AK, Chalasani N, Liu W, EASL meeting, 1/1/2013
• Serum keratin fragment 18 (CK18) levels significantly predict changes in liver histology in children and adolescents with nonalcoholic fatty liver disease (NAFLD): Res...
  Jain AK, Deppe RB, Yates KP, Comerford M, Masuoka HC, Molleston JP, Schwimmer JB, Lavine JE, Brunt EM, Tonascia J, Kleiner DE, Chalasani NP, AASLD, 1/1/2013
• Join now to see all

Lectures

• Initial Work-Up and Evaluation of a Patient With NAFLD 
  AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
• Advances in Non-Alcoholic Fatty Liver Disease (NAFLD) 
  AGC 2018 Annual Scientific Meeting, Philadelphia, PA - 10/8/2018
• Vitamin D deficiency in Chronic Liver Disease. 
  1/1/2012
• Single Topic Symposium on Nonalcoholic Fatty Liver Disease. 
  Kolkata, India - 1/1/2012
• Nonalcoholic Fatty Liver Disease. 
  1/1/2011
• Vitamin E in NAFLD symposium. 
  Bethesda, MD - 1/1/2011
• Genetic basis of drug induced liver injury. 
  1/1/2011
• Annual Liver Course. 
  Charleston, SC - 1/1/2009
• Using controlled clinical trials to learn more about acute drug-induced liver injury. 
  1/1/2008
• Drug induced liver injury - Standardization of nomenclature and causality. 
  1/1/2008
• AGA-Duke GI series. 
  1/1/2007
• Meet the GI Experts. 
  1/1/2007
• Portal Hypertension. 
  Atlanta, GA - 1/1/2007
• Annual Texas Hepatology Update . 
  San Antonio, TX, 2006, 2007 - 1/1/2007
• Drug Hepatotoxicity. 
  1/1/2007
• An overview of Chronic Liver Disease and Cirrhosis. 
  1/1/2006
• Academic Hepatology Workshop. 
  1/1/2006
• Steatohepatitis. 
  Atlanta, GA - 1/1/2006
• Statin Hepatotoxicity. 
  1/1/2005
• Statin Toxicity (Liver Safety Panel). 
  Washington, DC - 1/1/2005
• Primary Sclerosing Cholangitis. 
  Bethesda, MD - 1/1/2005
• Drug Induced Liver Injury. 
  Atlanta, GA - 1/1/2005
• Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. 
  Baveno, Italy - 1/1/2005
• Recommendations of liver expert panel. 
  Washington, DC - 1/1/2005
• Drug-induced liver injury: Summary of a single topic clinical research conference. 
  Atlanta, GA - 1/1/2005
• Join now to see all

Other

• NAFLD and it management. 
  Chalasani N (Series Ed), Clinical Liver Disease, an electronic publication of the AASLD
  1/1/2012